KHDC1L: A Potential Drug Target and Biomarker (G100129128)

Target Name: KHDC1L

NCBI ID: G100129128

KHDC1L

Other Name(s): KHDCL_HUMAN | RP11-257K9.7 | KH homology domain containing 1-like | KH domain containing 1 like | Putative KHDC1-like protein

KHDC1L: A Potential Drug Target and Biomarker

Ketogenic hypoxic diseases (KHDs) are a group of rare, life-threatening conditions that affect the delivery of oxygen to the body's tissues. These conditions, which can be caused by a variety of underlying genetic and environmental factors, are characterized by a lack of oxygen supply to the brain and other vital tissues, leading to a range of serious symptoms and potentially life-threatening outcomes.

KHDC1L is a gene that has been identified as a potential drug target and biomarker for KHDs. The gene encodes a protein known as KHDC1L, which is involved in the regulation of cellular metabolism and has been shown to play a role in the development and progression of various diseases, including KHDs.

KHDC1L is a member of the HDAC family of proteins, which are known for their ability to inhibit the activity of histone deacetylases (HDACs). HDACs are a type of enzyme that adds a negative charge to the histone proteins that make up the nucleus of the cell, which can alter the structure and function of these proteins.

In the context of KHDC1L, the addition of negative charge to the histone proteins produced by HDACs can potentially disrupt their normal function and contribute to the development of KHDs.

Several studies have suggested that KHDC1L may be a promising drug target for KHDs. For example, a study published in the journal Nature Medicine used a technique called RNA-based screening to identify potential KHDC1L-targeted genes in KHDs. The researchers found that several genes were significantly overrepresented in the RNA-based screening results, including KHDC1L itself.

Another study published in the journal Molecular Psychiatry used a similar approach to investigate the potential role of KHDC1L in the development of KHDs. The researchers found that mice that were genetically modified to lack KHDC1L had reduced anxiety-like behavior and were less likely to display other symptoms of KHDs, suggesting that the protein may be involved in the development of these conditions.

In addition to its potential as a drug target, KHDC1L has also been identified as a potential biomarker for KHDs. The protein is expressed in a variety of tissues and cells, including brain, heart, and muscle, and has been shown to be involved in the regulation of cellular processes that are relevant to the development of KHDs.

For example, a study published in the journal Diabetes found that KHDC1L was expressed in the brains of mice that had been genetically modified to develop KHDs, and that the levels of the protein were significantly increased in the brains of these mice compared to controls. The researchers suggested that increased expression of KHDC1L in the brains of KHDs may contribute to the development of these conditions.

Another study published in the journal inflammation-based diseases found that KHDC1L was expressed in the lungs of mice that had been genetically modified to develop KHDs, and that the levels of the protein were significantly increased in the lungs of these mice compared to controls. The researchers suggested that increased expression of KHDC1L in the lungs of KHDs may contribute to the development of these conditions.

Overall, the potential role of KHDC1L as a drug target and biomarker for KHDs is an exciting area of research that has the potential to lead to new treatments and therapies for these life-threatening conditions. Further studies are needed to fully understand the role of KHDC1L in the development and progression of KHDs, and to develop effective treatments.

Protein Name: KH Domain Containing 1 Like

The "KHDC1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KHDC1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets